Genomics to personalize care of prostate cancer

被引:1
作者
Connors, Laurie M. [1 ]
机构
[1] Vanderbilt Univ, Sch Nursing, 461 21st Ave South,213 Godchaux Hall, Nashville, TN 37240 USA
关键词
Genetic testing; genomics; personalize health care; prostate cancer;
D O I
10.1097/JXX.0000000000000390
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Prostate cancer is one of the most common cancers for men in the United States. Nurse practitioners need to understand oncology care and potential applications of genetic and genomics for men with prostate cancer. Genetic testing options are available to assist in decision making regarding screening for prostate cancer and the treatment of prostate cancer. Translating and integrating genomic test results can assist health care providers, patients, and their families to determine optimal and personalized oncology care in prostate cancer.
引用
收藏
页码:106 / 108
页数:3
相关论文
共 16 条
  • [1] American Cancer Society, 2019, EARL DET DIAGN STAG
  • [2] American Cancer Society, 2019, KEY STAT PROST CANC
  • [3] Mortality Results from a Randomized Prostate-Cancer Screening Trial
    Andriole, Gerald L.
    Grubb, Robert L., III
    Buys, Saundra S.
    Chia, David
    Church, Timothy R.
    Fouad, Mona N.
    Gelmann, Edward P.
    Kvale, Paul A.
    Reding, Douglas J.
    Weissfeld, Joel L.
    Yokochi, Lance A.
    Crawford, E. David
    O'Brien, Barbara
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hayes, Richard B.
    Kramer, Barnett S.
    Izmirlian, Grant
    Miller, Anthony B.
    Pinsky, Paul F.
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) : 1310 - 1319
  • [4] [Anonymous], 2019, ONCOTYPEDX
  • [5] Domchek S. M., 2017, CANCER DISCOV, DOI [10.1158/2159-8290.VD-17-0734, DOI 10.1158/2159-8290.VD-17-0734]
  • [6] FDA.gov, 2019, MSK IMPACTTM INT MUT
  • [7] Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States
    Kelly, Scott P.
    Anderson, William F.
    Rosenberg, Philip S.
    Cook, Michael B.
    [J]. EUROPEAN UROLOGY FOCUS, 2018, 4 (01): : 121 - 127
  • [8] PARP inhibitors: Synthetic lethality in the clinic
    Lord, Christopher J.
    Ashworth, Alan
    [J]. SCIENCE, 2017, 355 (6330) : 1152 - 1158
  • [9] DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
    Mateo, J.
    Carreira, S.
    Sandhu, S.
    Miranda, S.
    Mossop, H.
    Perez-Lopez, R.
    Rodrigues, D. Nava
    Robinson, D.
    Omlin, A.
    Tunariu, N.
    Boysen, G.
    Porta, N.
    Flohr, P.
    Gillman, A.
    Figueiredo, I.
    Paulding, C.
    Seed, G.
    Jain, S.
    Ralph, C.
    Protheroe, A.
    Hussain, S.
    Jones, R.
    Elliott, T.
    McGovern, U.
    Bianchini, D.
    Goodall, J.
    Zafeiriou, Z.
    Williamson, C. T.
    Ferraldeschi, R.
    Riisnaes, R.
    Ebbs, B.
    Fowler, G.
    Roda, D.
    Yuan, W.
    Wu, Y. -M.
    Cao, X.
    Brough, R.
    Pemberton, H.
    A'Hern, R.
    Swain, A.
    Kunju, L. P.
    Eeles, R.
    Attard, G.
    Lord, C. J.
    Ashworth, A.
    Rubin, M. A.
    Knudsen, K. E.
    Feng, F. Y.
    Chinnaiyan, A. M.
    Hall, E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18) : 1697 - 1708
  • [10] Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
    Mayrhofer, Markus
    De Laere, Bram
    Whitington, Tom
    Van Oyen, Peter
    Ghysel, Christophe
    Ampe, Jozef
    Ost, Piet
    Demey, Wim
    Hoekx, Lucien
    Schrijvers, Dirk
    Brouwers, Barbara
    Lybaert, Willem
    Everaert, Els
    De Maeseneer, Daan
    Strijbos, Michiel
    Bols, Alain
    Fransis, Karen
    Oeyen, Steffi
    van Dam, Pieter-Jan
    Van den Eynden, Gert
    Rutten, Annemie
    Aly, Markus
    Nordstrom, Tobias
    Van Laere, Steven
    Rantalainen, Mattias
    Rajan, Prabhakar
    Egevad, Lars
    Ullen, Anders
    Yachnin, Jeffrey
    Dirix, Luc
    Gronberg, Henrik
    Lindberg, Johan
    [J]. GENOME MEDICINE, 2018, 10